List of Ximino drug patents
Ximino is owned by Journey.
Ximino contains Minocycline Hydrochloride.
Ximino has a total of 6 drug patents out of which 0 drug patents have expired.
Ximino was authorised for market use on 11 July, 2012.
Ximino is available in capsule, extended release;oral dosage forms.
Ximino can be used as treatment of acne, treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
The generics of Ximino are possible to be released after 02 April, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268804 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
| US7790705 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
| US8252776 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Jun, 2025
(2 years from now) | |
| US7919483 | JOURNEY | Method for the treatment of acne |
Mar, 2027
(3 years from now) | |
| US7541347 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(4 years from now) | |
| US7544373 | JOURNEY | Minocycline oral dosage forms for the treatment of acne |
Apr, 2027
(4 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 11 July, 2012
Treatment: Treatment of acne; Treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
XIMINO family patents
23
United States
2
Japan
1
New Zealand
1
Australia
1
Norway
1
South Africa
1
Canada
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic